Video

Dr. Higgins on management of post-Aquablation blood loss

Author(s):

Urology Times staff
Conference|AUA

“From our standpoint, bigger prostates bleed more…From that, we started taking a different approach for those larger prostates,” says Andrew Higgins, MD.

In this video, Andrew Higgins, MD, discusses the background and findings of the study, “Prostate Aquablation: 2 years of perioperative outcomes,” presented recently at the 2021 American Urological Association annual meeting.

In the study, Higgins and coauthors implemented electrocautery protocols to mitigate blood loss among patients undergoing Aquablation.

Higgins is a urology resident at Einstein Healthcare Network, Philadelphia, Pennsylvania.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Colin Goudelocke, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Related Content
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
February 21st 2025

SoBPD: How many ways can you treat BPH or BPD?

Gopal H. Badlani, MD
"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor
“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
© 2025 MJH Life Sciences

All rights reserved.